Independent Financial Group LLC Purchases 57,994 Shares of Pfizer Inc. $PFE

Key Points

• Independent Financial Group increased its Pfizer stake by 90.4% in the second quarter, purchasing 57,994 additional shares for a total holding of 122,166 shares valued at approximately $2.94 million. Institutional investors collectively own 68.36% of Pfizer.
• Analysts maintain a generally cautious outlook, with Pfizer carrying a consensus “Hold” rating and an average price target of $28.28 versus a recent price of $26.77.
• Pfizer exceeded quarterly expectations with adjusted EPS of $0.77 and revenue of $15.03 billion, while offering a $0.43 quarterly dividend yielding about 6.4%. Investors remain focused on post-COVID revenue declines, asset impairments and pipeline execution risks.

Independent Financial Group LLC lifted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 90.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 122,166 shares of the biopharmaceutical company's stock after purchasing an additional 57,994 shares during the quarter. Independent Financial Group LLC's holdings in Pfizer were worth $2,942,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Handelsbanken Fonder AB increased its stake in Pfizer by 10.4% in the second quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company's stock valued at $59,295,000 after acquiring an additional 232,528 shares during the period. Vanguard Group Inc. raised its position in Pfizer by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company's stock worth $13,479,520,000 after purchasing an additional 7,031,162 shares in the last quarter. North Dakota State Investment Board bought a new position in Pfizer during the fourth quarter worth about $5,348,000. PFA Pension Forsikringsaktieselskab bought a new position in Pfizer during the fourth quarter worth about $76,833,000. Finally, John G Ullman & Associates Inc. boosted its holdings in Pfizer by 35.0% during the fourth quarter. John G Ullman & Associates Inc. now owns 206,065 shares of the biopharmaceutical company's stock valued at $5,131,000 after purchasing an additional 53,467 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on PFE shares. JPMorgan Chase & Co. lowered their price objective on Pfizer from $30.00 to $28.00 and set a "neutral" rating on the stock in a research note on Wednesday, July 8th. Wall Street Zen upgraded Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday, August 1st. UBS Group reaffirmed a "neutral" rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. Royal Bank Of Canada upgraded Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price target on the stock in a research report on Tuesday, June 9th. Finally, Citigroup increased their price objective on Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $28.28.

Pfizer Trading Down 0.1%

PFE opened at $26.77 on Friday. Pfizer Inc. has a 1-year low of $23.58 and a 1-year high of $28.75. The firm has a 50-day moving average price of $25.12 and a two-hundred day moving average price of $26.20. The stock has a market capitalization of $152.60 billion, a PE ratio of 35.23 and a beta of 0.34. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to analysts' expectations of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. Pfizer's revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.4%. Pfizer's dividend payout ratio is currently 226.32%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla purchased approximately $1 million of Pfizer stock—about 38,000 shares—in his first open-market purchase of the company’s shares. The transaction may reassure investors that management views the current valuation as attractive. Pfizer CEO Buys $1 Million of Company Stock
• Positive Sentiment: The European Medicines Agency validated Pfizer and Valneva’s application for their six-valent Lyme disease vaccine candidate, PF-07307405, beginning the formal review process. The filing is supported by Phase 3 results showing more than 70% efficacy and no significant safety concerns. Validation is an important regulatory milestone, although it does not represent approval. Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
• Positive Sentiment: An updated Korean real-world study of Paxlovid highlighted continued potential value for high-risk COVID-19 patients, supporting Pfizer’s effort to maintain demand for its antiviral as COVID-related revenue normalizes. Pfizer’s Korean Paxlovid Study Signals Ongoing Value in High-Risk COVID Market
• Neutral Sentiment: Erste Group Bank raised its fiscal 2026 EPS forecast, adding modest analyst support. Pfizer’s broader investment case also continues to rely on its non-COVID portfolio, including positive Phase 3 LITFULO data and recently acquired products.
• Negative Sentiment: Investors remain focused on Pfizer’s post-COVID revenue declines, recent intangible-asset impairments, and the discontinuation of its BEQVEZ hemophilia gene therapy, which underscore execution and pipeline risks. Gene Therapy Remains Top-of-Mind in Hemophilia

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source